Genetic engineering of death ligands for improvement of therapeutic activity

Advances in Experimental Medicine and Biology

Volumn 691, Issue , 2011, Pages 507-519

  Gerspach, Jeannette ^a   Schneider, Britta ^a   Müller, Nicole ^b   Otz, Tina ^a   Wajant, Harald ^b   Pfizenmaier, Klaus ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CD19 TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND FUSION PROTEIN; CD40 FAS LIGAND FUSION PROTEIN; CD40 TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND FUSION PROTEIN; CD70 ANTIGEN; DEATH RECEPTOR; DEATH RECEPTOR 5; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ALPHA SINGLE CHAIN TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND FUSION PROTEIN; FAS LIGAND; GELATINASE A; HYBRID PROTEIN; PRODRUG; RITUXIMAB; SEPRASE; SEPRASE FAS LIGAND FUSION PROTEIN; SEPRASE SINGLE CHAIN TUMOR NECROSIS FACTOR LIGAND FUSION PROTEIN; SEPRASE SINGLE CHAIN TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND FUSION PROTEIN; SEPRASE TUMOR NECROSIS FACTOR LIGAND FUSION PROTEIN; SEPRASE TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND FUSION PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE FAS LIGAND FUSION PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE TUMOR NECROSIS FACTOR LIGAND FUSION PROTEIN; TENASCIN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR NECROSIS FACTOR;

ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; CELL DEATH; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONFERENCE PAPER; ENZYME ACTIVITY; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; IN VIVO STUDY; INTRACELLULAR SIGNALING; LEUKEMIA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN IMMOBILIZATION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN STRUCTURE; PROTEIN TARGETING; TUMOR XENOGRAFT; ANIMAL; ARTICLE; DRUG EFFECT; METHODOLOGY; NEOPLASM; PATHOLOGY; PROTEIN MULTIMERIZATION; PROTEIN STABILITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; FAS LIGAND PROTEIN; GENETIC ENGINEERING; HUMANS; NEOPLASMS; PRODRUGS; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; RECOMBINANT FUSION PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTORS;

EID: 79954429561     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6612-4_53     Document Type: Conference Paper

References (28)

1. Assohou-Luty C, Gerspach J, Siegmund D, Muller N, Huard B, Tiegs G, Pfizenmaier K, Wajant H (2006) A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. J Mol Med 84:785-797
2. Berg D, Lehne M, Muller N, Siegmund D, Munkel S, Sebald W, Pfizenmaier K, and Wajant H (2007) Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ 14:2021-2034
3. Bremer E, Kuijlen J, Samplonius D,Walczak H, de Leij L, and HelfrichW(2004) Target cellrestricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 109:281-290
4. Bremer E, Samplonius DF, Peipp M, van Genne L, Kroesen BJ, Fey GH, Gramatzki M, de Leij LF, and Helfrich W (2005) Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res 65:3380-3388
5. Bremer E, Samplonius DF, van Genne L, Dijkstra MH, Kroesen BJ, de Leij LF, and Helfrich W (2005) Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 280:10025-10033
6. Bremer E, ten Cate B, Samplonius DF, de Leij LF, and Helfrich W (2006) CD7-restricted activation of Fas-mediated apoptosis: A novel therapeutic approach for acute T-cell leukemia. Blood 107:2863-2870
7. Bremer E, ten Cate B, Samplonius DF, Mueller N, Wajant H, Stel AJ, Chamuleau M, van de Loosdrecht AA, Stieglmaier J, Fey GH, and Helfrich W (2008) Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. Cancer Res 68: 597-604
8. Corti A, Fassina G, Marcucci F, Barbanti E, and Cassani G (1992) Oligomeric tumour necrosis factor alpha slowly converts into inactive forms at bioactive levels. Biochem J 284 (Pt 3), 905-910
9. Gerspach J, Muller D, Munkel S, Selchow O, Nemeth J, Noack M, Petrul H, Menrad A, Wajant H, and Pfizenmaier K (2006) Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug. Cell Death Differ 13:273-284
10. Gerspach J, Nemeth J, Munkel S, Wajant H, and Pfizenmaier K (2006) Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface. Cancer Immunol Immunother 55:1590-1600
11. Gerspach J, Wajant H, and Pfizenmaier K (2009) Death ligands designed to kill: Development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. Results Probl Cell Differ 49:241-273
12. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, and Scheurich P (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:793-802
13. Kammerer RA, Schulthess T, Landwehr R, Lustig A, Fischer D, and Engel J (1998) Tenascin-C hexabrachion assembly is a sequential two-step process initiated by coiled-coil alpha-helices. J Biol Chem 273:10602-10608
14. Krippner-Heidenreich A, Grunwald I, Zimmermann G, Kuhnle M, Gerspach J, Sterns T, Shnyder SD, Gill JH, Mannel DN, Pfizenmaier K, and Scheurich P (2008) Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J Immunol 180:8176-8183
15. Lejeune FJ, Lienard D, Matter M, and Ruegg C (2006) Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6:6
16. Muller N, Wyzgol A, Munkel S, Pfizenmaier K, and Wajant H (2008) Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization. FEBS J 275:2296-2304
17. O'Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, Haynes NM, Tarlinton DM, Zhang JG, Belz GT, Smyth MJ, Bouillet P, Robb L, and Strasser A (2009) Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 461:659-663
18. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, and Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364:806-809
19. Poiesi C, Albertini A, Ghielmi S, Cassani G, and Corti A (1993) Kinetic analysis of TNFalpha oligomer-monomer transition by surface plasmon resonance and immunochemical methods. Cytokine 5:539-545
20. Razmara M, Hilliard B, Ziarani AK, Murali R, Yellayi S, Ghazanfar M, Chen YH, and Tykocinski ML (2009) Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis. Am J Pathol 174:460-474
21. Samel D, Muller D, Gerspach J, Assohou-Luty C, Sass G, Tiegs G, Pfizenmaier K, andWajant H (2003) Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation. J Biol Chem 278:32077-32082
22. Schneider B, Münkel S, Krippner-Heidenreich A, Grunwald I, Wels WS, Wajant H, Pfizenmaier K and Gerspach J (2009) Potent antitumoral activity of TRAIL through generation of tumor - targeted single - chain fusion proteins. Cell Death Disease, accepted
23. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, and Tschopp J (1998) Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187: 1205-1213
24. Stieglmaier J, Bremer E, Kellner C, Liebig TM, ten Cate B, Peipp M, Schulze-Koops H, Pfeiffer M, Buhring HJ, Greil J, Oduncu F, Emmerich B, Fey GH, and Helfrich W (2008) Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol Immunother 57:233-246
25. ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, and Helfrich W (2009) A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia 23:1389-1397
26. Wajant H, Moosmayer D, Wuest T, Bartke T, Gerlach E, Schonherr U, Peters N, Scheurich P, and Pfizenmaier K (2001) Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 20:4101-4106
27. Watermann I, Gerspach J, Lehne M, Seufert J, Schneider B, Pfizenmaier K, and Wajant H (2007) Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death Differ 14:765-774
28. Wyzgol A, Muller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K, and Wajant H (2009) Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoidinduced TNF receptor ligand J Immunol 183:1851-1861